Form D · Pharmaceuticals

Equilibre BioPharmaceuticals Corp.

New York, NY · CIK 0001831900

Offering snapshot reported Dec 1, 2022 · SEC filing

Reported sold: $6M
Investors reported: 13
Minimum accepted: $0
First sale: Nov 16, 2022

Fundraising history

Reported sold

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Dec 1, 2022	Initial	$6,000,002	No comparison	13	SEC filing
Dec 1, 2022	Amendment	$6,000,002	$0vs Dec 1, 2022	13	SEC filing
Jan 20, 2022	Initial	$15,902,341	No comparison	14	SEC filing
Nov 12, 2020	Initial	$25,799,973	No comparison	14	SEC filing

Offering details

Securities: Equity
Exemptions: 06b
Duration over one year: No
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-466233

Source: Form D, filed Dec 1, 2022. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Philip A. Barach	Director, Executive
David Friedman	Director
Steven N. Gordon	Director, Executive
Francois Maisonrouge	Director
Joel Marcus	Director
Christina Ramirez	Director
Peter M. Simon	Director
Christopher Thorn	Executive
Samuel Waksal	Director, Executive
Sam Waksal	Executive

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:

430 E 29th St.
New York, NY, 10016